104,967 Shares in Johnson & Johnson $JNJ Purchased by Leo Wealth LLC

Leo Wealth LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 104,967 shares of the company’s stock, valued at approximately $27,789,000. Johnson & Johnson accounts for 5.9% of Leo Wealth LLC’s portfolio, making the stock its largest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Jupiter Topco LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $1,967,399,000. Diamant Asset Management Inc. increased its holdings in Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. Corient Private Wealth LP increased its holdings in Johnson & Johnson by 127.3% in the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after purchasing an additional 3,393,981 shares during the last quarter. Wellington Management Group LLP increased its holdings in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Finally, Amundi lifted its stake in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Guggenheim restated a “buy” rating and set a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Wells Fargo & Company upped their price target on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a research report on Thursday, October 15th. Finally, Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Trading Up 0.9%

JNJ opened at $271.17 on Thursday. The stock has a market capitalization of $652.78 billion, a P/E ratio of 41.09, a P/E/G ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The firm’s fifty day simple moving average is $265.60 and its 200 day simple moving average is $246.26. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.